OverviewSuggest Edit

Interpace Diagnostics is a health care commercialization company providing insight-driven, integrated multi-channel message delivery for health care companies. The Company is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.

TypePublic
Founded1987
HQParsippany-Troy Hills, NJ, US
Websiteinterpace.com
Overall CultureB-

Latest Updates

Employees (est.) (Feb 2019)89(+19%)
Revenue (FY, 2020)$32.4 M(+34%)
Share Price (Oct 2021)$8.6(+2%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Interpace Diagnostics

Stephen J. Sullivan

Stephen J. Sullivan

Director
Thomas Burnell

Thomas Burnell

President and CEO, Director
Greg Richard

Greg Richard

Chief Commercial Officer
Joseph Keegan

Joseph Keegan

Director
Edward Chan

Edward Chan

Director
Fred Knechtel

Fred Knechtel

Chief Financial Officer
Show more

Interpace Diagnostics Office Locations

Interpace Diagnostics has offices in Parsippany-Troy Hills, Morrisville and Pittsburgh
Parsippany-Troy Hills, NJ, US (HQ)
300 Interpace Pkwy, Parsippany
Morrisville, NC, US
133 Southcenter Ct #400
Pittsburgh, PA, US
2515 Liberty Ave
Show all (3)

Interpace Diagnostics Financials and Metrics

Interpace Diagnostics Revenue

Embed Graph
View revenue for all periods
Interpace Diagnostics's revenue was reported to be $32.4 m in FY, 2020
USD

Revenue (FY, 2020)

32.4m

Gross profit (FY, 2020)

10.7m

Gross profit margin (FY, 2020), %

33.1%

Net income (FY, 2020)

(26.5m)

EBIT (FY, 2020)

(26.1m)

Market capitalization (22-Oct-2021)

35.6m

Closing stock price (22-Oct-2021)

8.6

Cash (31-Dec-2020)

2.8m

EV

36.3m
Interpace Diagnostics's current market capitalization is $35.6 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

157.3m126.9m150.8m119.9m9.4m13.1m15.9m21.9m24.2m32.4m

Revenue growth, %

(20%)(92%)39%

Cost of goods sold

124.8m100.0m126.4m101.4m6.9m6.6m7.4m10.2m15.9m21.7m

Gross profit

32.5m26.9m24.4m18.5m2.5m6.4m8.5m11.7m8.3m10.7m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

64.3m52.8m45.6m23.1m8.3m602.0k15.2m6.1m2.3m2.8m

Accounts Receivable

9.6m10.7m2.4m8.5m2.8m2.2m3.4m9.5m10.3m8.0m

Prepaid Expenses

3.7m6.1m6.6m7.2m2.6m1.2m2.2m

Current Assets

80.4m71.6m62.7m44.9m19.2m4.2m19.8m17.7m16.5m14.1m
USDQ2, 2011

Financial Leverage

1.7 x
Show all financial metrics

Interpace Diagnostics Operating Metrics

FY, 2016

Facilities

2

Patents (Foreign)

3

Patents (US)

1

Products

3
Show all operating metrics

Interpace Diagnostics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Interpace Diagnostics Online and Social Media Presence

Embed Graph

Interpace Diagnostics Company Culture

  • Overall Culture

    B-

    77/100

  • CEO Rating

    A+

    100/100

  • Compensation

    C+

    73/100

Learn more on Comparably

Interpace Diagnostics News and Updates

Interpace Diagnostics Announces US Patent Approval for Patent Application No. 11,118, 231 B2 Titled: microRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms

PARSIPPANY, NJ, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for improved patient diagnosis and management, today…

Interpace Diagnostics Issues Update Regarding Announced Contract with BCBS of Massachusetts

Parsippany, NJ, March 11, 2020 (GLOBE NEWSWIRE) -- Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced today that it has entered into a contract with Blue Cross Blue Shield of Massachusetts. While terms of this Agreement are not disclosed, Interpace is an in-netwo…

Interpace Diagnostics Announces Contract with BCBS of Massachusetts

In-Network Access for More Than 3 Million Members

Interpace Diagnostics Announces Publication of New Data on Thyroid Test Utility

Clinical Data Highlights the Utility of ThyGeNEXT® and ThyraMIR®

Thinking about buying stock in Beyond Meat, DGSE, Interpace Diagnostics, Melinta Therapeutics, or Oracle?

NEW YORK, June 20, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BYND, DGSE, IDXG, MLNT, and ORCL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Interpace Diagnostics Announces Coverage of Molecular Thyroid Testing by Independence Blue Cross

PARSIPPANY NJ, June 20, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that its ThyGeNEXT™ and ThyraMIR® tests for thyroid cancer are now covered by Independence Blue Cross (Independence), providing plan benefits coverage for its members who meet establis…
Show more

Interpace Diagnostics Blogs

Interpace Diagnostics Reports Third Quarter 2018 Financial Results, Business Progress and Recent Accomplishments

Conference Call Tuesday, November 13, 2018 at 4:30 pm ET PARSIPPANY, NJ,, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. IDXG, +0.84% a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for im…

Interpace Diagnostics to Host Conference Call and Webcast to Discuss Third Quarter 2018 Financial Results on Tuesday, November 13, 2018

Interpace Diagnostics Group, Inc. IDXG, +1.48% announced today that it will report its third quarter 2018 financial results after the close of market on Tuesday, November 13, 2018 at 4:30 p.m. ET. Following the announcement, Interpace will host a conference call and webcast to discuss the Company's …

Interpace Diagnostics Presents Favorable New Data at the 88th Annual Meeting of the American Thyroid Association (ATA)

ThyGenX® and ThyraMIR® Data from Clinical Experience Study Shows Positive Results  PARSIPPANY, NJ, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. IDXG, +1.47% announced that the Company presented new data at the 88th Annual Meeting of the American Thyroid Association (ATA) on Fr…

Interpace Diagnostics CEO Provides Corporate Update

Interpace Diagnostics Group IDXG, -6.15% is pleased to provide a corporate update to shareholders on current business activities from its Chief Executive Officer, Jack Stover.   "I would like to share my gratitude for each of you and my confidence and pride in the future of Interpace Diagnostics Gro…

Interpace Diagnostics to Present New Data at the 88th Annual Meeting of the American Thyroid Association (ATA) on October 5th

ThyGenX® and ThyraMIR® Data from Clinical Experience Study to be Featured at ATA Product Expo  PARSIPPANY, NJ, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. IDXG, +8.44% announced today that it will be presenting new data from a multi-center Clinical Experience Study at the 88t…

Interpace Diagnostics Supports Research Efforts of Pancreatic and Thyroid Cancer Patient Advocacy Groups

Interpace Employees Participate in Local Events in Support of Lustgarten Foundation for Pancreatic Cancer Research, Thyroid, Head and Neck Cancer Foundation, and Pancreatic Cancer Action Network  PARSIPPANY, NJ, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. IDXG, +2.11% ("Inte…
Show more

Interpace Diagnostics Frequently Asked Questions

  • When was Interpace Diagnostics founded?

    Interpace Diagnostics was founded in 1987.

  • Who are Interpace Diagnostics key executives?

    Interpace Diagnostics's key executives are Stephen J. Sullivan, Thomas Burnell and Greg Richard.

  • How many employees does Interpace Diagnostics have?

    Interpace Diagnostics has 89 employees.

  • What is Interpace Diagnostics revenue?

    Latest Interpace Diagnostics annual revenue is $32.4 m.

  • What is Interpace Diagnostics revenue per employee?

    Latest Interpace Diagnostics revenue per employee is $364 k.

  • Who are Interpace Diagnostics competitors?

    Competitors of Interpace Diagnostics include Navigere, Microcoat Biotechnologie and One Lambda.

  • Where is Interpace Diagnostics headquarters?

    Interpace Diagnostics headquarters is located at 300 Interpace Pkwy, Parsippany, Parsippany-Troy Hills.

  • Where are Interpace Diagnostics offices?

    Interpace Diagnostics has offices in Parsippany-Troy Hills, Morrisville and Pittsburgh.

  • How many offices does Interpace Diagnostics have?

    Interpace Diagnostics has 3 offices.